Express Mail No.: EL 452 480 802 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Boehm et al.

Serial No.: 09/743,953 Group Art Unit: 1615

Filed: March 12, 2001 Examiner: To be assigned

O I P & For: INHIBITION OF ALOPECIA Attorney Docket No.: 8484-095-999

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

- 1. Enclosures accompanying this Information Disclosure Statement are:
 - 1a.

 A list of all patents, publications, applications, or other information submitted for consideration by the office.
 - 1b. A legible copy of:
 - Each U.S. patent application publication and U.S. and foreign patent;
 - Each publication or that portion which caused it to be listed on the PTO-1449;
 - □ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
 - all other information or portion which caused it to be listed on the PTO-1449.
 - 1c.

 An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
 - 1d.

 Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
- 2.
 ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
 - □ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);

			hin three months of the date of entry of the national stage as set forth in §1.491 in an rnational application;							
	Ø	Bef	ore the mailing of the first Office action on the merits;							
	0		ore the mailing of a first Office action after the filing of a request for continued mination under §1.114.							
0	in 3 a no	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.								
	(Check either Item 3a or 3b)									
3a.			The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.							
3b.			The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is: □ enclosed □ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.							
	(Ite	m 31	to be checked if any reference known for more than 3 months)							
0		this Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified a 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.								
	The \$180.00 fee set forth in 37 C.F.R. §1.17(i)(1) is: — enclosed. — to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.									
The Certification Statement in Item 5 below is applicable.										
_	□ Certification Statement (applicable if Item 3a or Item 4 is checked)									
			(Check either Item 5a or 5b)							
5a.		0	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.							
5b.		0	In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.							

3. □

4. 🗆

5. □

6.

This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

6a.

A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

	6b.				listed on Form PTO-1449 from prior application Serial in application claims priority under 35 U.S.C. §120, are 37 C.F.R. §1.98(d).			
	6c.				listed on Form PTO-1449 were not previously cited in ed on , and are provided herewith.	prior		
7.		Thi	s is a	a Supplemental Information	Disclosure Statement. (Check either Item 7a or 7b)			
	7a.		0	supplements the Information made to comply with 37 C omissions have been correct	ation Disclosure Statement under 37 C.F.R. §1.97(f) on Disclosure Statement filed on A bona fide attem .F.R. §1.98, but inadvertent omissions were made. The cted herein. Accordingly, additional time is requested stion Disclosure Statement can be considered as if proper	se so that		
	7b.		0	This Supplemental Information of a PTO Notice under 37	ation Disclosure Statement is timely filed within one (1) C.F.R. §1.97(i).) month		
8.	0	In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood the relevance of each non-English language publication is:						
				(CF	heck Item 8a, 8b, or 8c)			
	8a.			English language copy of t	nglish language publications were cited on the enclosed the PCT International Search Report or the search report ation indicating the degree of relevance found by the for	t from a		
	8b.			set forth in the application.				
	8c.			enclosed as an attachment	hereto.			
9.	⊠	The Commissioner is authorized to charge any additional fee required or credit any overpaymen for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150.						
10.	Ø	No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).						
Date		July	<u>, 19,</u>	2001 B	Respectfully submitted, Wreit Millauer Off 77 Or Laura A. Coruzzi (Reg. No. 30,742) PENNIE & EDMONDS LLP 155 Avenue of Americas New York NY 10036-2720 212) 790 - 9090	<u>43,341</u> eg. No.)		

Sheet	1	of	1	

					ATTY, DOCKET NO.		APPLICATION NO.					
					8484-0095-999	09/743,953						
	LISTO	F REFERENCES CITE	ED BY APPLI	CANT	APPLICANT							
		(Use several sheets if	necessary)		Boehm et al.	Boehm et al.						
					FILING DATE		GROUP					
					January 12, 2001		1615					
			U.	S. PATENT DOCL	MENTS							
*EXAMINER	DOCUMENT NUMBER DATE			NAME		SUBCLASS	FILING DATE					
INITIAL				 				IF APPROPRIATE				
\		FOREIGN PATENT DOCUMENTS										
OIPE		DOCUMENT NUMBER	DATE	EIGN PATENT DO	COUNTRY	CLASS	Τ	TRANSLATION				
	(3)		DATE		COUNTRY	CLASS	SUBCLASS	YES	NO			
JUL 192	MAY A	DD 58 358 A	11/09/67	Cormony (Sta	kov et al.)			123	, <u>"</u>			
<u> </u>		DD 36 336 A	11/09/67	Germany (Sto	KOV et al.)				-			
TO ESTA	ARB ARB	WO 91/02538	8/17/90	PCT (Rothma	n <i>et al</i> .)							
, OEM	AC	DE 197 36 198 C	12/24/98	Germany (De				:				
				Offentlichen F	ngszentrum Stiftung des Rechts)							
	100		4/4.4/0.0		<u> </u>							
	AD	WO 98/46208	4/14/98	PCT (Weiner	et al.)	- !		<u> </u>]			
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)											
	AE	Bertolino <i>et al.</i> , 1990, "Differential expression of type I hair keratins," <u>J. Invest. Dermatol.</u> <u>94</u> :297-303										
	AF	Bernd et al., 1994, "Effect of Minoxidil on the Mobility and Differentiation of Cultivated Human Keratinocytes," <u>ArzneimForsch./Drug Res.</u> , <u>44</u> : 137-140. Fink et al., 1995, "A cDNA encoding the human type I hair keratin hHal." Biochim, Biophys, Acta							nan			
	AG											
	АН											
	Kain et al., 1995, "Green fluorescent protein as a reporter of gene expression and protein localization," Biotechniques 19(4):650-655 Kurooka et al., 1996, "Rescue of the hairless phenotype in nude mice by transgenic insertion of the wild-type Hfh11 genoic locus," Int. Immunol. 8(6):961-966											
									d-			
	AK	Nehls <i>et al.</i> , 1996, "Two genetically separable steps in the differentiation of thymic epithelium," <u>Science</u> 272:886-889										
	AL	Schorpp et al., 1997, "Characterization of mouse and human nude genes," Immunogenetics 46:509-515							5			
	АМ	Schuddekopf <i>et al.</i> , 1996, "The whn transcription factor encoded by the <i>nude</i> locus contains an evolutionarily conserved and functionally indispensable activation domain," <u>Proc. Natl. Acad. Sci. U.S.A. 93</u> :9661-9664										
EXAMINER	1			DATI	CONSIDERED							

		if reference considered, what not considered. Include			ince with MPEP 609; Draw lining	through cita	ition if not					